Autopsy report · NCT05123040

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

“Sponsor terminated financial support”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 7 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Acute-graft-versus-host Disease

Interventions

Ruxolitinib 10 MG Oral Tablet; hCG; Corticosteroids

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
  “Sponsor Terminated” (88% match in meaning)
• Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
  “Loss of Financial Sponsor” (86% match in meaning)
• 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
  “loss of sponsor support” (85% match in meaning)
• Pazopanib in Molecularly Selected Patients With Advanced NSCLC
  “Terminated by sponsor” (85% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.